[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours].
Shumin Deng
Abstract
Shumin Deng
Abstract
Phosphodiesterase type 5 (PDE5) inhibitors are first-line oral medication for erectile dysfunction (ED). Compared with the other two PDE inhibitors (sildenafil and vardenafil), tadalafil is characterized by rapid onset, convenient dosing, excellent efficacy, especially the 36-hour duration of effectiveness deriving from long elimination half-life, allowing for more flexibility to scheduled medication. Higher satisfaction of patients and their partners with tadalafil is mainly due to such psychosocial benefits as decreased time concerns. Tadalafil is well-tolerated, consistent with the principle of safely, effectiveness and convenient dosing and is becoming the favorite choice of ED patients and their partners.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Phosphodiesterase type 5 (PDE5) inhibitors are first-line oral medication for erectile dysfunction (ED). Compared with the other two PDE inhibitors (sildenafil and vardenafil), tadalafil is characterized by rapid onset, convenient dosing, excellent efficacy, especially the 36-hour duration of effectiveness deriving from long elimination half-life, allowing for more flexibility to scheduled medication. Higher satisfaction of patients and their partners with tadalafil is mainly due to such psychosocial benefits as decreased time concerns. Tadalafil is well-tolerated, consistent with the principle of safely, effectiveness and convenient dosing and is becoming the favorite choice of ED patients and their partners.
Key concepts: Tadalafil, Vardenafil, Erectile dysfunction, Medicine, Dosing, Psychosocial, cGMP-specific phosphodiesterase type 5, Sildenafil